October 5, 2020
Chugai Pharmaceutical said on October 2 that it has submitted applications in Japan seeking the expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for the FGFR inhibitor pemigatinib and the TRK inhibitor larotrectinib. Pemigatinib by Incyte...read more